loader from loading.io

Emerging Pharmacotherapies and Future Perspectives for Obesity Treatment

Fireside Chats on Endocrinology and Metabolism in the Mantzoros lab

Release Date: 01/22/2024

Emerging Pharmacotherapies and Future Perspectives for Obesity Treatment show art Emerging Pharmacotherapies and Future Perspectives for Obesity Treatment

Fireside Chats on Endocrinology and Metabolism in the Mantzoros lab

Obesity is described by many as the epidemic of the 21st century. Currently, limited and suboptimal drugs are available to the clinician’s therapeutic armamentarium. However, novel agents and combination schemes, mainly with Incretin Analogs, seem to be revolutionizing the way we will soon be treating overweight and obesity. In this podcast, we discuss notable drug advancements and concepts of novel agents, the need for metabolism clinics for the interaction of various medical specialties, and bariatric/metabolic surgery in managing individuals with chronic metabolic conditions. There is...

info_outline
ESPAÑOL: De Hígado Graso No Alcohólico (NAFLD) a Enfermedad Hepática Esteatósica Asociada a Disfunción Metabólica (MASLD) show art ESPAÑOL: De Hígado Graso No Alcohólico (NAFLD) a Enfermedad Hepática Esteatósica Asociada a Disfunción Metabólica (MASLD)

Fireside Chats on Endocrinology and Metabolism in the Mantzoros lab

Este episodio es la traducción en español de nuestra conversación con el Dr. Christos Mantzoros, profesor y endocrinólogo de la Facultad de Medicina de Harvard, sobre el cambio de la terminología de Hígado Graso No Alcohólico (NAFLD por sus siglas en íngles) hacia la Enfermedad Hepática Esteatósica Asociada a Disfunción Metabólica (MASLD). Además hablaremos de la importancia de esta nueva nomenclatura y sus implicaciones en la clínica y la investigación. El consenso que guió el cambio, hacia a una terminología más precisa y apropiada, está respaldado por los avances en la...

info_outline
From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD), an update of the new terminology and its significance show art From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD), an update of the new terminology and its significance

Fireside Chats on Endocrinology and Metabolism in the Mantzoros lab

In this episode, Dr. Christos Mantzoros, Professor and Endocrinologist at Harvard Medical School and the editor-in-chief of the Journal Metabolism: Clinical and Experimental, will guide the discussion about the ongoing journey towards refining the NAFLD terminology to Steatotic Liver Disease (SLD) and will shed light to the significance of the recent nomenclature change.  The consensus to shift to a new, more accurate, and appropriate name is underpinned by the advances in understanding the multisystem and multifactorial pathophysiology of metabolic dysfunction-associated steatotic liver...

info_outline
ESPAÑOL: Lo que debes saber de Obesidad: ¿Qué tan frecuente es la obesidad, cómo desarrollamos la obesidad y por qué es importante? show art ESPAÑOL: Lo que debes saber de Obesidad: ¿Qué tan frecuente es la obesidad, cómo desarrollamos la obesidad y por qué es importante?

Fireside Chats on Endocrinology and Metabolism in the Mantzoros lab

La obesidad es la epidemia del siglo XXI, pero ¿qué es y por qué la desarrollamos?   ¿Es una enfermedad? ¿Existe la obesidad metabólicamente saludable y la no saludable?   ¡Bienvenido a la serie sobre la obesidad! En este primer episodio, presentaremos conceptos críticos sobre cómo desarrollamos la obesidad y por qué es importante.   ¡Estén atentos de nuestros siguientes episodios de obesidad!   Los autores poseen los derechos de autor de todos los contenidos de este Podcast. Reservados todos los derechos. Los usuarios de este Podcast pueden guardar y usar la...

info_outline
Obesity 101:  How Prevalent Is Obesity, How Do We Develop Obesity, and Why It Matters? show art Obesity 101: How Prevalent Is Obesity, How Do We Develop Obesity, and Why It Matters?

Fireside Chats on Endocrinology and Metabolism in the Mantzoros lab

Obesity is the global epidemic of the 21st century, but what is it, and why do we develop it?   Is it a disease? Is there metabolically healthy and unhealthy obesity?   Welcome to the obesity series! In this first episode, we will present critically important concepts on how we develop obesity and why it matters.   There is more to come, please stay tuned!   The authors own the copyright to all the contents of this Podcast. All rights reserved. Users of this Podcast may save and use the information contained in the Podcast only for personal or other non-commercial...

info_outline
ESPAÑOL: Enfermedad del hígado graso: una necesidad clínica no satisfecha show art ESPAÑOL: Enfermedad del hígado graso: una necesidad clínica no satisfecha

Fireside Chats on Endocrinology and Metabolism in the Mantzoros lab

La enfermedad del hígado graso no alcohólico (NAFLD, por sus siglas en inglés) es una importante epidemia de salud pública estrechamente relacionada con las epidemias de obesidad y síndrome metabólico. Su prevalencia, combinada con los avances recientes de la investigación, requiere que los endocrinólogos y los médicos de atención primaria participen en la identificación y el manejo de las personas afectadas o en riesgo de desarrollar esta enfermedad. Bienvenidos a nuestro episodio "Enfermedad del hígado graso: una necesidad clínica no satisfecha"; Hay más por venir en nuestro...

info_outline
Fatty Liver Disease: An Unmet Clinical Need show art Fatty Liver Disease: An Unmet Clinical Need

Fireside Chats on Endocrinology and Metabolism in the Mantzoros lab

Nonalcoholic fatty liver disease (NAFLD) is a major public health epidemic closely linked to the epidemics of obesity and the metabolic syndrome. Its prevalence, combined with recent research advances, necessitates that endocrinologists and primary care physicians are involved in identifying and managing persons affected by, or at risk for developing this disease.   Welcome to our episode Fatty Liver Disease: An Unmet Clinical Need; There is more to come, please stay tuned!         The authors own the copyright to all the contents of this Podcast. All rights reserved....

info_outline
Español: Introducción ¡Bienvenidos a nuestro Podcast! show art Español: Introducción ¡Bienvenidos a nuestro Podcast!

Fireside Chats on Endocrinology and Metabolism in the Mantzoros lab

Bienvenidos al primer episodio de nuestro podcast  ¡Estamos muy emocionados de que te unas a nosotros! Gracias por estar acá,   El Mantzoros Lab, ¡Apasionados por la Endocrinología, la Innovación y la Mentoría!

info_outline
Introduction, Welcome To Our Podcast! show art Introduction, Welcome To Our Podcast!

Fireside Chats on Endocrinology and Metabolism in the Mantzoros lab

Welcome to the first episode of the Fireside Chats on Endocrinology and Metabolism in the Mantzoros Lab. We are so excited you are joining us! Thank you, The Mantzoros Lab.  Passionate about Endocrinology, Innovation, and Mentoring!       The following music was used for this media project: Music: Total Happy Up And Sunny by Sascha Ende. License (CC BY 4.0): . Artist website: https://www.sascha-ende.de

info_outline
 
More Episodes

Obesity is described by many as the epidemic of the 21st century. Currently, limited and suboptimal drugs are available to the clinician’s therapeutic armamentarium. However, novel agents and combination schemes, mainly with Incretin Analogs, seem to be revolutionizing the way we will soon be treating overweight and obesity. In this podcast, we discuss notable drug advancements and concepts of novel agents, the need for metabolism clinics for the interaction of various medical specialties, and bariatric/metabolic surgery in managing individuals with chronic metabolic conditions.

There is more to come; please stay tuned!

 

 

The authors own the copyright to all the contents of this Podcast. All rights reserved. Users of this Podcast may save and use the information contained in the Podcast only for personal or other non-commercial purposes. No other use, including, but not limited to, educational, reproduction, retransmission or editing, of this Podcast may be made without the prior written permission of the authors. Permission may be requested by contacting the authors via email. Disclaimer: The information, statements, opinions and/or recommendations presented are solely those of the authors and are offered for general education only; any reliance on or use of the information provided in this Podcast is done at the listener's discretion and risk. This Podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. If you are not a medical doctor, please always seek the advice of your physician or other qualified licensed health care provider regarding any decision or action related to any medical condition or treatment and before undertaking a new therapy; never disregard professional medical advice or delay in seeking it due to information you have heard in this Podcast. The authors assume no responsibility or liability for the accuracy or completeness of the content contained herein and/or in any third-party materials. Finally, authors make no warranty that this Podcast, or the server that makes it available, is free of viruses, worms, or other elements or codes that may have contaminating or destructive properties. Authors expressly disclaim any and all liability or responsibility for any direct, indirect, incidental, special, consequential, or other damages arising out of any individual's use of, reference to, reliance on, or inability to use this podcast or the information presented in this podcast.